Dronedarone in the management of atrial fibrillation

Linker, Nicholas J.; Nelson, Katharine E.
July 2011
British Journal of Cardiac Nursing;Jul2011, Vol. 6 Issue 7, p327
Academic Journal
Atrial fibrillation is an abnormal heart rhythm involving disorded electrical activiy in the atria, leading to irregular contraction of the ventricles. Overall heart rate is usually faster than in sinus rhythm. At present, drug therapy continues to be the mainstay of treatment for atrial fibrillation, and may consist of rate control or rhythm control (plus stroke prophylaxis). Dronedarone is a relatively new antiarrhythmic drug, developed as an alternative to amiodarone. This article discusses its characteristics and potential role in management of AF.


Related Articles

  • Real-World Observations with Dronedarone Compared to Other Anti-Arrhythmic Drugs in Recurrent Atrial Fibrillation. Demarie, D.; Orlando, F.; Imazio, M.; Cerrato, E.; Richiardi, E.; Belli, R.; Said, Sam // British Journal of Medicine & Medical Research;2015, Vol. 5 Issue 9, p1088 

    Background: Many clinical trials have shown that dronedarone which is a potent ion channels blocker is effective in the prevention of atrial fibrillation (AF) relapses. Objective: The aim of this report is to evaluate the recurrence of AF and safety during therapy with dronedarone. Methods: From...

  • Amiodarone.  // Reactions Weekly;12/18/2010, Issue 1332, p8 

    The article describes the case of a 58-year-old man who developed pulmonary injury while receiving treatment with antiarrhythmic amiodarone, referencing a study published in the August 2010 issue of the journal "Kokyu to Junkan."

  • FDA actions. Elliott, William T. // Primary Care Reports;Feb2012 Pharmacology Watch, p2 

    The article discusses several FDA actions, including approval to generic atorvastatin (Lipitor) by Ranbaxy Laboratories and Prevnar 13 by Wyeth Pharmaceuticals; and the requirement for revised labeling of Dronedarone (Multaq), for patients with permanent atrial fibrillation (AF).

  • The Efficacy and Tolerability of Commonly Used Agents to Prevent Recurrence of Atrial Fibrillation After Successful Cardioversion. Gonna, Hanney; Gallagher, Mark // American Journal of Cardiovascular Drugs;Aug2014, Vol. 14 Issue 4, p241 

    A number of therapeutic strategies exist for the restoration and maintenance of sinus rhythm in patients presenting with atrial fibrillation. The acute success rate with electrical cardioversion is high. However, many patients relapse into atrial fibrillation. A major challenge faced by those...

  • Ventricular Tachycardia (VT): Mechanism to Management. MARDELL, ANDREW P.; EXNER, DEREK V. // Fire Engineering;Jun2010, Vol. 163 Issue 6, p28 

    The article explores the mechanisms of different types of ventricular tachycardia (VT), electrocardiographic (ECG) criteria to diagnose VT and VT management. VT can be categorized as monomorphic or polymorphic. Primary mechanisms that result in cardiac arrhythmias include abnormal automaticity,...

  • Atrial Fibrillation. Trappe, Hans-Joachim // Deutsches Aerzteblatt International;1/9/2012, Vol. 109 Issue 1/2, p1 

    Background: 5% to 8% of 70-year-olds and some 10% of persons over age 80 have atrial fibrillation (AF). Methods: Selective literature review. Results: New scoring schemes (CHA2DS2-VASc score, HASBLED score) have been introduced to enable more accurate estimation of the risk of stroke and...

  • Intravenous vernakalant: a guide to its use in recent-onset atrial fibrillation.  // Drugs & Therapy Perspectives;Aug2011, Vol. 27 Issue 8, p6 

    Intravenous vernakalant is effective in the rapid termination of recent-onset atrial fibrillation in both nonsurgical patients and post-cardiac surgery patients, and is generally well tolerated. In keeping with the more rapid onset of action of vernakalant, sinus rhythm conversion rates are...

  • Dronedarone: Uncertainties Continue to Emerge Over Its Role in the Treatment of Atrial Fibrillation. Howard, Patricia A. // Hospital Pharmacy;May2012, Vol. 47 Issue 5, p338 

    The article focuses on the role of the drug dronedarone in the treatment of permanent atrial fibrilatiion (AF). It says that the drug has been approved by the U.S Food and Drug Administration (FDA) for patients with paroxysmal or persistent AF. It adds that the drug should not be used for...

  • Intravenous Vernakalant: A Review of its Use in the Management of Recent-Onset Atrial Fibrillation. Duggan, Sean T.; Scott, Lesley J. // Drugs;2011, Vol. 71 Issue 2, p237 

    Intravenous vernakalant (Brinavess®) is an atrial-repolarization-delaying agent that is currently approved in the EU for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm. Vernakalant blocks atrial-specific potassium and sodium ion channels, prolonging atrial refractory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics